论文部分内容阅读
目的观察卡培他滨单药或联合奥沙利铂同步放化疗对晚期直肠癌的临床疗效。方法 52例晚期直肠癌患者随机分为试验组和对照组,每组26例。2组均采取6 m V的X射线进行照射,每周5次,共5周。放疗的同时,对照组用卡培他滨单药化疗,每天2次,总剂量为1500~1700 mg·m~(-2)。试验组静脉滴注奥沙利铂总剂量为50~75 mg·m~(-2),每周1次,卡培他滨每天2次,总剂量为1200~1550 mg·m~(-2),每个周期均为35 d,2组均治疗3个周期。观察2组患者的临床疗效、生活质量改善及不良反应发生情况。结果治疗后,试验组患者客观缓解率(76.93%)显著高于对照组(42.31%,P<0.05);试验组生活质量的改善情况显著优于对照组(P<0.05);试验组患者不良反应率显著低于对照组(P<0.05)。结论卡培他滨联合奥沙利铂同步放化疗治疗晚期直肠癌患者疗效较好,不良反应相对较低,可改善患者的生活质量,有利于患者预后。
Objective To observe the curative effect of capecitabine monotherapy or oxaliplatin combined with concurrent chemoradiotherapy on advanced rectal cancer. Methods 52 patients with advanced colorectal cancer were randomly divided into experimental group and control group, with 26 cases in each group. Both groups took 6 mV X-ray irradiation, 5 times a week for 5 weeks. At the same time of radiotherapy, the control group was treated with capecitabine alone twice a day for a total dose of 1500-1700 mg · m -2. The total dose of oxaliplatin in the experimental group was 50-75 mg · m -2, once a week, twice a day for capecitabine, and the total dose was 1200-1550 mg · m -2 ), Each cycle was 35 d, two groups were treated 3 cycles. The clinical efficacy, quality of life and the incidence of adverse reactions in the two groups were observed. Results After treatment, the objective response rate (76.93%) in the experimental group was significantly higher than that in the control group (42.31%, P <0.05); the quality of life in the experimental group was significantly better than that in the control group (P <0.05) Response rate was significantly lower than the control group (P <0.05). Conclusions Both capecitabine and oxaliplatin concurrent chemoradiotherapy are effective in patients with advanced rectal cancer. The adverse reactions are relatively low, which can improve the quality of life of patients and benefit the prognosis of patients.